You are here: Home » PTI Stories » National » News
Business Standard

Pfizer withdraws Corex syrup, extends line to new products

Press Trust of India  |  New Delhi 

Drug maker is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio.

The company has also decided to discontinue the manufacturing of current Corex cough syrup formulation.



"The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year," said in a statement.

"The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation. stands by the safety and efficacy of its current Corex Syrup formulation that has been duly approved by the central and state regulator," It added.

In March this year, had discontinued manufacture and sale of its popular cough syrup Corex after the banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.

According to Pfizer, with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place.

"remains committed to provide a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex syrup formulation," it said.

Before the ban, Corex Cough Syrup had sales of Rs 244.48 crore in FY 2015-16.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Pfizer withdraws Corex syrup, extends line to new products

Drug maker Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio. The company has also decided to discontinue the manufacturing of current Corex cough syrup formulation. "The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year," Pfizer said in a statement. "The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation. Pfizer stands by the safety and efficacy of its current Corex Syrup formulation that has been duly approved by the central and state regulator," It added. In March this year, Pfizer had discontinued manufacture and sale of its popular cough syrup Corex after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup. According to Pfizer, with this formulation, all ... Drug maker is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio.

The company has also decided to discontinue the manufacturing of current Corex cough syrup formulation.

"The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year," said in a statement.

"The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation. stands by the safety and efficacy of its current Corex Syrup formulation that has been duly approved by the central and state regulator," It added.

In March this year, had discontinued manufacture and sale of its popular cough syrup Corex after the banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.

According to Pfizer, with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place.

"remains committed to provide a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex syrup formulation," it said.

Before the ban, Corex Cough Syrup had sales of Rs 244.48 crore in FY 2015-16.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Pfizer withdraws Corex syrup, extends line to new products

Drug maker is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio.

The company has also decided to discontinue the manufacturing of current Corex cough syrup formulation.

"The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year," said in a statement.

"The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation. stands by the safety and efficacy of its current Corex Syrup formulation that has been duly approved by the central and state regulator," It added.

In March this year, had discontinued manufacture and sale of its popular cough syrup Corex after the banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.

According to Pfizer, with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place.

"remains committed to provide a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex syrup formulation," it said.

Before the ban, Corex Cough Syrup had sales of Rs 244.48 crore in FY 2015-16.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard